HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 20, No 12, December 2016 – Medical Imaging Technology       » Climate Change Could Hurt Coffee, Help Banana Production       » Partnerships and Innovation: Shaping the Future of Healthcare in Asia Pacific       » Chugai's Novel Antibody Technologies Put Singapore at the Centre of Fight Against Disease       » NUS Scientists Discover the "Switch" that Makes Breast Cancer Cells Aggressive      
EYE ON CHINA
EntreMed files new drug clinical trial application for ENMD-2076 with China SFDA to advance global development strategy
EtreMed, Inc. (ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, announced their submission of a new drug clinical trial application with China's State Food and Drug Administration (SFDA) for its proprietary drug candidate, ENMD-2076, to conduct global clinical trials in triple-negative breast cancer patients.

Ken K. Ren, Ph.D., EntreMed's Chief Executive Officer, commented, “We are very pleased with SFDA's acceptance of our application package and look forward to working with the SFDA to move the process forward towards approval. SFDA's approval of our application would pave the way for us to conduct global clinical trials in China and advance our ongoing Phase II triple-negative breast cancer trial currently underway at the University of Colorado and Indiana University.

“Our filing with SFDA represents an important milestone for us. As a clinical-stage drug development company, competition in patient recruitment, time, and costs can be challenging when advancing clinical programs. We address this by building a value-added platform via a joint US-China drug development model that will enable us to do the trials with lower study costs and faster patient recruitment. The data we obtain may be used to support both global drug development and China import drug registration as appropriate.”

Dr. Ren continued, “We will also pursue developing ENMD-2076 in other indications where activity has been shown, including ovarian cancer, sarcoma and liver cancer, based on our prioritized product development plan. We believe positive results from these efforts will add value to our patients, shareholders, as well as to the company.

“In addition, we have initiated local manufacturing and pre-clinical activities of ENMD-2076 in China to target specific unmet medical needs, such as hepatocellular carcinoma, which could support a new drug trial application with SFDA. Our local development activities demonstrate EntreMed's commitment to develop a strong presence in the Chinese market, which has been projected to become the second largest pharmaceutical market in coming years. We believe we are on track with our development plan and are grateful to our shareholders for their enthusiasm, patience, and long term support.”

Click here for the complete issue.

NEWS CRUNCH  
news Accuron Technologies' MedTech Division Invests into AWAK Technologies
news Philips introduces PerformanceBridge suite of operational performance improvement software and services for radiology departments
news Give a Gift that Will Last a Lifetime this Holiday Season with Smile Train
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Lungs & Respiratory System
February:
Cancer Research, Treatment/Technology
March:
Traditional Chinese Medicines
April:
Eye Care/ Eye Health
May:
The Piece of Your Mind - Brain Health/Science
June:
Featuring Biotech Start-Ups/Companies
July:
Food Science & Technology
August:
Diabetics Technology
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy